ProSomnus to Present at Two Upcoming Investor Conferences in March 2023

Rhea-AI Summary

ProSomnus (NASDAQ: OSA), a leader in precision medical devices for Obstructive Sleep Apnea (OSA), announced participation in two investor conferences in March 2023. The conferences are the 35th Annual Roth Conference from March 12-14 and the 33rd Annual Oppenheimer Healthcare Conference from March 13-15. CEO Len Liptak and other executives will engage in discussions, with a fireside chat scheduled for March 13 at 3:30 pm PT and a presentation on March 14 at 1:40 pm PT, both accessible via live webcasts. ProSomnus is recognized for its FDA-cleared, patient-preferred devices, which effectively treat OSA, impacting over 74 million North Americans.

News Market Reaction – OSA

-1.19%

1 alert

-1.19% News Effect

On the day this news was published, OSA declined 1.19%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

SAN FRANCISCO, March 01, 2023 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (“the Company”) (NASDAQ: OSA), a pioneer in precision medical devices for the treatment of Obstructive Sleep Apnea (OSA), today announces that Company management will participate in two investor conferences in the month of March 2023:

• 35^th Annual Roth Conference on March 12-14, 2023
• 33^rd Annual Oppenheimer Healthcare Conference on March 13-15, 2023

About 35^th Annual Roth Conference

ProSomnus’ Chief Executive Officer, Len Liptak, Executive Chair, Laing Rikkers, and Chief Financial Officer, Brian Dow, will engage in a fireside chat during the Roth Annual Conference, which will be held at the Ritz Carlton, Laguna Niguel on March 12-14, 2023.

The fireside chat is scheduled for Monday, March 13 at 3:30 pm Pacific Time / 6:30 pm Eastern Time and will be accessible via a live webcast here. A replay of discussion will be available after the conclusion of the live discussion on the Investor Relations section of the Company’s website.

About 33^rd Annual Oppenheimer Healthcare Conference

ProSomnus’ Chief Executive Officer, Len Liptak, Executive Chair, Laing Rikkers, and Chief Financial Officer, Brian Dow, will deliver a presentation during the Oppenheimer Annual Healthcare Conference, which will be held virtually on March 13-15, 2023.

The presentation is scheduled on Tuesday, March 14 at 1:40 pm Pacific Time / 4:40 pm Eastern Time and will be accessible via a live webcast here. A replay of presentation will be available after the conclusion of the live presentation on the Investor Relations section of the Company’s website.

About ProSomnus

ProSomnus (NASDAQ: OSA) precision intraoral medical devices offer effective, economical, and patient preferred treatment for patients suffering from Obstructive Sleep Apnea. ProSomnus is the first manufacturer of mass-customized Precision Oral Appliance Therapy (OAT) devices to treat OSA, which affects over 74 million people in North America and is associated with serious comorbidities, including heart failure, stroke, hypertension, morbid obesity, and type 2 diabetes. ProSomnus’s patented, FDA-cleared devices are a less invasive and more comfortable alternative to Continuous Positive Airway Pressure (CPAP) therapy, and lead to more effective and patient-preferred outcomes. A growing body of research, including studies published by the Journal of Clinical Sleep Medicine and Military Medicine, suggests ProSomnus’s Precision OAT devices are an effective treatment for mild to moderate OSA. Additional clinical research has shown that ProSomnus’s Precision OAT devices mitigate many of the side effects associated with alternative treatments and improve economics for payers and providers. With more than 187,500 devices delivered, ProSomnus’s devices are the most prescribed Precision OAT in the U.S. ProSomnus’s FDA-cleared devices are authorized by the Department of Defense and the U.S. Army, and are often covered by medical insurance, Medicare, and social health programs in key international markets. To learn more, visit www.ProSomnus.com.

Investor Contact
Mike Cavanaugh
ICR Westwicke
Phone: +1.617.877.9641
Email: Mike.Cavanaugh@westwicke.com

Media Contact
Kyle Evans
ICR Westwicke
Phone: +1.646.277.1295
Email: Kyle.Evans@westwicke.com

FAQ

What are the upcoming investor conferences for ProSomnus in March 2023?

ProSomnus will participate in the 35th Annual Roth Conference from March 12-14 and the 33rd Annual Oppenheimer Healthcare Conference from March 13-15, 2023.

When is ProSomnus' fireside chat during the Roth Conference?

The fireside chat is scheduled for March 13, 2023, at 3:30 pm Pacific Time.

How can I access the live presentation of ProSomnus at the Oppenheimer Healthcare Conference?

The presentation will be available via live webcast on March 14, 2023, at 1:40 pm Pacific Time.

What is the focus of ProSomnus' medical devices?

ProSomnus specializes in precision intraoral medical devices for the treatment of Obstructive Sleep Apnea (OSA).

How many devices has ProSomnus delivered to date?

ProSomnus has delivered more than 187,500 devices, making it the most prescribed Precision Oral Appliance Therapy in the U.S.